Illumina, Inc. (ILMN) Stock Analysis
Healthcare · Diagnostics & Research
Wait for pullback to $130.01. Weak momentum — blocks BUY_NOW at $140.79. Engine's entry $130.01 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: sequencing revenue (92.0%); Analyst target reached - limited upside remaining.
Illumina is a global provider of sequencing and array-based solutions for genetic and genomic analysis, serving research centers, clinical labs, pharmaceutical companies, and consumer genomics firms. Sequencing represented 92% of total revenue in 2025 with ~48% from... Read more
Wait for pullback to $130.01. Weak momentum — blocks BUY_NOW at $140.79. Engine's entry $130.01 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: sequencing revenue (92.0%); Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Score 4.8/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 71d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
Recent Developments — Illumina, Inc.
Latest news
- Illumina Inc. (ILMN) - Q1 2026 Earnings Preview: Key Metrics, Sector Context and Investor Expectations - High Attention — Newser neutral
- Unlocking Q1 potential of Illumina (ILMN): Exploring Wall Street estimates for key metrics - MSN — MSN positive
- Unlocking Q1 Potential of Illumina (ILMN): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance — Yahoo Finance positive
- Illumina (ILMN) Q1 Earnings Report Preview: What To Look For - StockStory — StockStory neutral
- Illumina (ILMN) Q1 earnings report preview: What to look for - MSN — MSN neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductsequencing revenue92%10-K Item 1: 'In 2025, 2024, and 2023, total sequencing revenue comprised 92%, 91%, and 91%, respectively, of total revenue'
- MEDIUMGeographicGreater China10-K Item 1A: 'Our revenue from the Greater China region, which includes China, Taiwan, and Hong Kong, was $243 million in 2025'
Material Events(8-K, last 90d)
- 2026-04-02Item 5.02LOWDirectors Frances Arnold, Robert Epstein, and Gary Guthart notified the Board of their intention to retire as directors effective May 21, 2026 (2026 annual meeting). Retirements not the result of any dispute or disagreement. Board nominated David King for election.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $130.01. Weak momentum — blocks BUY_NOW at $140.79. Engine's entry $130.01 (Ma50 Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: sequencing revenue (92.0%); Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. | News modifier +2 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Target $147.20 (+4.6%), stop $118.41 (−18.9%), Setup A.R:R 1.9:1. Score 4.8/10, moderate confidence.
Take-profit target: $147.20 (+13.2% upside). Target $147.20 (+4.6%), stop $118.41 (−18.9%), Setup A.R:R 1.9:1. Stop-loss: $118.41.
Concentration risk — Product: sequencing revenue (92.0%); Analyst target reached - limited upside remaining; Weak overall score: 4.8/10.
Illumina, Inc. trades at a P/E of 25.8 (forward 23.9). TrendMatrix value score: 4.3/10. Verdict: Buy (Wait for Entry).
28 analysts cover ILMN with a consensus score of 3.7/5. Average price target: $144.
What does Illumina, Inc. do?Illumina is a global provider of sequencing and array-based solutions for genetic and genomic analysis, serving...
Illumina is a global provider of sequencing and array-based solutions for genetic and genomic analysis, serving research centers, clinical labs, pharmaceutical companies, and consumer genomics firms. Sequencing represented 92% of total revenue in 2025 with ~48% from international customers; the company had a backlog of $738M as of December 28, 2025. China regulatory inclusion on the List of Unreliable Entities has constrained instrument exports, with Greater China revenue of $243M in 2025.